| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Trillium Therapeutics Inc. | Chief Scientific Officer | Stock Option (Right to Buy) | 0 | 17 Nov 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000110465921141739-uger-robert-2021-11-17 | Trillium Therapeutics Inc. | 17 Nov 2021 | 6 | $0 | 4 | Chief Scientific Officer | 19 Nov 2021, 12:23 |
| /report/000106299321006419-uger-robert-2021-07-07 | Trillium Therapeutics Inc. | 07 Jul 2021 | 3 | -$31,706 | 4 | Chief Scientific Officer | 09 Jul 2021, 16:30 |
| /report/000106299321005487-uger-robert-2021-06-07 | Trillium Therapeutics Inc. | 07 Jun 2021 | 3 | -$29,004 | 4 | Chief Scientific Officer | 09 Jun 2021, 16:23 |
| /report/000106299321004390-uger-robert-2021-05-07 | Trillium Therapeutics Inc. | 07 May 2021 | 3 | -$32,767 | 4 | Chief Scientific Officer | 11 May 2021, 16:24 |